SLFN12 and glioblastoma: We characterized PDE3A and SLFN12 expression in commercial glioblastoma cell lines and glioblastoma neurospheres.23 We validated velcrin sensitivity in a subset of both glioblastoma cell lines and glioblastoma neurospheres and determined that PDE3A expression is the key driver of sensitivity in both sets of models.